Spots Global Cancer Trial Database for Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer
Official Title: A Phase Ib Study of Erlotinib in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Previously Untreated Advanced Pancreatic Cancer
Study ID: NCT01010945
Conditions
Study Description
Brief Summary: This is a phase 1b study to evaluate the combination of gemcitabine and Tarceva (erlotinib) and nab-paclitaxel in patients with advanced pancreatic cancer.
Detailed Description: This is a single-arm, phase 1b study to determine the maximum tolerated dose (MTD) of the combination of erlotinib (daily), gemcitabine (weekly), nab-paclitaxel (weekly) in patients with advanced pancreatic cancer.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Desert Comprehensive Cancer Center, Palm Springs, California, United States
University of Colorado Cancer Center, Aurora, Colorado, United States
University of North Carolina, Chapel Hill, North Carolina, United States
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Vanderbilt Ingram Cancer Center, Nashville, Tennessee, United States
Contact Details
Name: Medical Monitor
Affiliation: Astellas Pharma Global Development
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
